Trulieve Cannabis Corp. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $230.2 million (-20.1% year over year) and diluted EPS of $0.00. It usually reports 36–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
230
-20.1%
|
1
+102.7%
|
0.00
+100.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
287
-3.7%
|
2
+106.8%
|
0.01
+107.6%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
293
-2.7%
|
-44
+29.2%
|
-0.22
+28.9%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
288
+1.4%
|
-29
+53.5%
|
-0.14
+56.2%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
302
-0.4%
|
-16
-30.9%
|
-0.07
-80.2%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
298
+0.0%
|
-34
-35.9%
|
-0.16
+0.0%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
301
+4.9%
|
-62
-77.0%
|
-0.31
-77.9%
|
|
Nov 5, 2024
36 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TRLV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Tallahassee, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1754195
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.